drugset / Trial / NCT04102124
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
RandomizedParallel-groupTriple-blindTreatment
Summary
The aim of this trial is to evaluate SHR3680 combined with SHR3162 and SHR3680 single drug to improve Metastatic Castration Resistant Prostate Cancer Patients whether the patient's overall survival (OS) is superior to placebo.
Timeline
- Start
- 2019-04-08
- Primary completion
- 2021-08-31
- Completion
- 2021-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluzoparib | Small molecule | 10 mg | Oral |
| Subject | Fluzoparib | Small molecule | 40 mg | Oral |
| Subject | Fluzoparib | Small molecule | 50 mg | Oral |
| Subject | Fluzoparib | Small molecule | 100 mg | Oral |
| Subject | Rezvilutamide | Small molecule | 80 mg | Oral |